Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:30 AM PST. The conference will take place January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.
About Arena
Pharmaceuticals
Arena Pharmaceuticals is driven to
deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease, as well as in programs for
primary biliary cholangitis (PBC) and atopic dermatitis. Ralinepag (APD811) is being evaluated
in a Phase 3 program for pulmonary arterial hypertension (PAH).
Arena is also evaluating olorinab (APD371) in a Phase 2 program
for gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including
APD418 for decompensated heart
failure.
In addition, Arena has several partnerships including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).
Forward-Looking Statements
Certain
statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. These
forward-looking statements may be accompanied by words such as
"will," "driven to," "potentially," "potential," or words of
similar meaning, or they may be identified by the fact that they do
not relate strictly to historical or current facts. Such
forward-looking statements include, without limitation, statements
about Arena's drive, focus, goals, strategy, clinical and research
and development programs, and collaborations. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements
include the closing of Arena's announced licensing agreement
with United Therapeutics regarding ralinepag, which is subject to
regulatory approval and other conditions; the timing and
outcome of research, development and regulatory review is
uncertain; clinical programs may not proceed at the time or in the
manner expected or at all; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; and other risks related to developing
and commercializing drugs; as well as those factors disclosed in
Arena's filings with the Securities and Exchange
Commission (SEC), including but not limited to Arena's
Quarterly Report on Form 10-Q for the quarter ended September
30, 2018, which was filed with the SEC on November
8, 2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman,
MD
LifeSci Public Relations
[email protected]
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-on-january-10-300768611.html